1 day Ago By ABMN Staff
Rocket Pharmaceuticals ( NASDAQ:RCKT – Get Free Report ) ‘s stock had its “buy” rating reissued by stock analysts at Needham & Company LLC in a note issued to investors on Tuesday, Benzinga reports. They currently have a $52.00 target price on the biotechnology company’s stock.
Needham & Company LLC’s target price points to a potential upside of 149.52% from the stock’s current price. Several other research firms have also recently weighed in on RCKT.
William Blair reaffirmed an “outperform” rating on shares of Rocket Pharmaceuticals in a research report on Monday, June 3rd. JPMorgan Chase & Co. upped their price target on Rocket Pharmaceuticals from $50.
00 to $54.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 6th. Chardan Capital reissued a “buy” rating and set a $62.
00 price objective on shares of Rocket Pharmaceuticals in a research report on Tuesday, August 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 target price on shares of Rocket Pharmaceuticals in a research report on Tuesday, August 6th.
Finally, Canaccord Genuity Group lowered their price target on shares of Rocket Pharmaceuticals from $49.00 to $40.00 and set a “buy” rating for the company in a research report on Wednesday, July 3rd.
One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $52.
29. View Our Latest Research Report on Rocket Pharmaceuticals Rocket Pharmaceuticals Price Performance Rocket Pharmaceuticals ( NASDAQ:RCKT – Get Free Report ) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.
74) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.02).
During the same quarter in the previous year, the company posted ($0.82) earnings per share. Research analysts predict that Rocket Pharmaceuticals will post -2.
97 earnings per share for the current year. Insiders Place Their Bets In other Rocket Pharmaceuticals news, insider Mark Andrew White sold 3,026 shares of the stock in a transaction on Monday, July 8th. The stock was sold at an average price of $20.
39, for a total value of $61,700.14. Following the sale, the insider now owns 72,220 shares in the company, valued at $1,472,565.
80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website . 31.
10% of the stock is owned by insiders. Hedge Funds Weigh In On Rocket Pharmaceuticals A number of hedge funds and other institutional investors have recently modified their holdings of the business. Nisa Investment Advisors LLC raised its position in shares of Rocket Pharmaceuticals by 31.
9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,160 shares of the biotechnology company’s stock worth $68,000 after acquiring an additional 764 shares in the last quarter. Old Well Partners LLC bought a new position in Rocket Pharmaceuticals in the fourth quarter worth about $200,000.
Capstone Investment Advisors LLC purchased a new stake in shares of Rocket Pharmaceuticals during the fourth quarter valued at about $217,000. Amalgamated Bank boosted its holdings in shares of Rocket Pharmaceuticals by 5.4% in the 4th quarter.
Amalgamated Bank now owns 8,653 shares of the biotechnology company’s stock valued at $259,000 after buying an additional 440 shares in the last quarter. Finally, Dana Investment Advisors Inc. grew its position in shares of Rocket Pharmaceuticals by 4.
4% in the 2nd quarter. Dana Investment Advisors Inc. now owns 13,847 shares of the biotechnology company’s stock worth $298,000 after buying an additional 586 shares during the last quarter.
98.39% of the stock is currently owned by institutional investors. About Rocket Pharmaceuticals ( Get Free Report ) Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases.
It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. Featured Articles Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
